Semaglutide is a GLP-1 receptor agonist sold as Ozempic for type 2 diabetes and Wegovy for chronic weight management. Doctors often need to submit prior authorization (PA) requests to insurers before coverage begins. Without PA approval, patients usually pay full price out of pocket.
Prior authorization criteria exist to ensure the medication is medically necessary and meets specific clinical guidelines. Insurers want proof that other treatments were tried or that the patient has qualifying conditions. These rules vary by plan type and payer.
Understanding the most common requirements helps patients and providers prepare stronger submissions. Meeting the criteria increases approval chances and reduces delays.
Why Prior Authorization Is Required for Semaglutide
Insurance companies use prior authorization to control costs on high-priced specialty drugs. Semaglutide can cost $1,000 or more per month at list price, so payers want confirmation it is appropriate for the individual.
PA also ensures the drug is used for approved indications or supported off-label uses. For diabetes, approval is usually straightforward. For weight loss, criteria become stricter because obesity treatment has historically been limited.
The process protects against overuse while allowing access for patients who truly need it. Most commercial plans and some Medicaid programs require PA for semaglutide when prescribed for weight management.
Medicare Part D rarely covers Wegovy for obesity alone due to federal exclusions, so PA is not applicable in those cases. Ozempic for diabetes typically bypasses PA in many plans.
Common Prior Authorization Criteria for Diabetes Use (Ozempic)
When semaglutide is prescribed for type 2 diabetes, criteria focus on diagnosis confirmation and basic safety checks. Most plans require documented type 2 diabetes with an A1C above a certain threshold or inadequate control on other therapies.
Insurers often ask for recent A1C results, usually within the last three to six months. They may require proof that metformin was tried or is contraindicated before approving a GLP-1 agonist.
Cardiovascular or kidney benefits can strengthen the case. Ozempic is approved to reduce major adverse cardiovascular events in patients with established heart disease and to slow kidney disease progression in diabetic patients with albuminuria.
Contraindications must be ruled out. Plans check for personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease.
PA for diabetes use is often approved quickly when basic documentation exists. Denials usually stem from missing labs or incomplete forms rather than strict clinical barriers.
Prior Authorization Criteria for Weight Loss Use (Wegovy)
Weight-loss indications face the toughest requirements. Nearly all commercial plans demand a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity.
Common comorbidities include hypertension, dyslipidemia, prediabetes, type 2 diabetes, obstructive sleep apnea, or osteoarthritis of weight-bearing joints. Chart notes or lab results must support these diagnoses.
Documented lifestyle intervention is almost always required. Plans typically want evidence of participation in a structured diet and exercise program for at least three to six months with insufficient results.
Some insurers enforce step therapy. Patients may need to try older weight-loss agents, metformin, or intensive behavioral therapy before a GLP-1 agonist is approved.
Continued coverage often depends on achieving a minimum weight-loss threshold, such as 5% of baseline weight after three to six months. Lack of progress can lead to discontinuation of authorization.
Here are the most frequent PA criteria for Wegovy across commercial plans:
- BMI ≥30 or ≥27 with documented comorbidity
- Age 18 years or older
- Failure of at least three to six months of lifestyle modification
- No contraindications (thyroid cancer history, pancreatitis, etc.)
- Prescriber attestation of medical necessity
- Regular follow-up and weight monitoring required
Step Therapy and Quantity Limits in PA Requests
Step therapy forces patients to try lower-cost or older treatments first. For weight loss, plans may require a trial of phentermine, orlistat, metformin, or behavioral counseling before approving semaglutide.
Quantity limits restrict the number of pens per fill or per month. Most plans allow one pen every 28 days to match weekly dosing, with no refills until the previous supply is nearly finished.
Dose escalation must follow FDA labeling. PA often specifies starting at 0.25 mg and increasing gradually to maintenance doses like 2.4 mg for Wegovy.
Some plans cap the maximum duration of coverage or require periodic re-authorization every six to twelve months. These rules encourage ongoing evaluation of benefit.
Comparison of Prior Authorization Criteria: Commercial vs Medicaid vs Medicare
| Payer Type | BMI Requirement | Lifestyle Trial Required |
|---|---|---|
| Commercial/Private | ≥30 or ≥27 + comorbidity | Yes, 3–6 months |
| Medicaid (varies by state) | ≥30 or ≥27 + comorbidity | Yes, often longer |
| Medicare Part D | Not applicable for weight loss | N/A |
Commercial plans have the most consistent but detailed criteria. Medicaid coverage depends heavily on state policy. Medicare blocks weight-loss-only use nationwide.
Required Documentation for a Strong PA Submission
A complete PA packet improves approval odds. Include current BMI calculation with date, height, and weight measurements.
Attach progress notes showing comorbidities with supporting labs or diagnostic reports. Hypertension needs blood pressure readings; prediabetes needs A1C or fasting glucose values.
Provide records of prior weight-loss attempts. Dietitian notes, gym logs, or patient-reported efforts over several months strengthen the case.
Include the prescribing physician’s letter of medical necessity. This should explain risks of untreated obesity, previous failures, and expected benefits of semaglutide.
Recent labs ruling out contraindications, such as thyroid function tests or pancreatic enzyme levels, help avoid automatic denials.
How Long Prior Authorization Takes and What to Expect
Most commercial plans process PA requests within three to fourteen days. Urgent requests can sometimes be expedited to 72 hours when health risks justify faster review.
Medicaid timelines vary by state but often take seven to twenty-one days. Managed care organizations may process faster than fee-for-service plans.
If approved, authorization usually lasts six to twelve months. Re-authorization requires updated weight records and proof of continued benefit.
Denials come with a letter explaining the reason. Common reasons include insufficient documentation, step therapy not completed, or BMI below threshold.
Appeals can reverse many denials. Submit additional evidence within the plan’s deadline, typically 60 to 180 days.
Tips to Avoid or Overcome PA Denials
Work with an obesity medicine specialist or endocrinologist when possible. Their detailed notes carry more weight than general primary care documentation.
Start gathering records early. Keep a file with BMI history, comorbidity labs, lifestyle attempt summaries, and progress photos or measurements.
Submit the PA request well before the current supply runs out. Delays can leave patients without medication if approval takes longer than expected.
Use peer-to-peer reviews when offered. Your doctor can speak directly with the insurer’s medical reviewer to clarify medical necessity.
If PA fails repeatedly, ask about switching to a covered indication. Borderline prediabetes or cardiovascular risk factors sometimes qualify under broader criteria.
Alternatives When Prior Authorization Is Denied
Compounded semaglutide through licensed telehealth providers costs $199–$399 monthly and bypasses insurance requirements. These versions require a medical evaluation but offer consistent access.
Manufacturer self-pay programs provide Wegovy at $199 introductory then $349 monthly for eligible patients without adequate coverage. These are direct from Novo Nordisk and guarantee brand-name quality.
Other GLP-1 medications like tirzepatide may have different PA criteria in some plans. Switching can sometimes unlock approval.
Intensive behavioral therapy, nutrition counseling, or bariatric surgery evaluations are often covered under Medicaid and commercial plans. These provide non-drug pathways for weight management.
Monitoring and Re-Authorization Requirements
Once approved, plans monitor progress closely. Weight must be submitted every three to six months, often with proof of at least 5% loss from baseline.
Continued authorization depends on sustained benefit. Plateaus or weight regain can lead to discontinuation unless the doctor justifies ongoing need.
Regular blood work may be requested to monitor safety, especially kidney function, thyroid levels, and A1C if diabetic.
Patients should keep follow-up appointments and maintain communication with their prescriber. Missing visits or labs can trigger PA termination.
Conclusion
Semaglutide prior authorization criteria focus on BMI thresholds, comorbidities, lifestyle trial history, and ongoing benefit proof. Commercial plans enforce the strictest rules, while Medicaid varies by state and Medicare excludes weight-loss-only use. Prepare complete documentation, appeal denials promptly, and explore self-pay or compounded options when needed to improve access.
FAQ
What BMI is usually required for semaglutide prior authorization?
Most plans require BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity such as hypertension, prediabetes, or sleep apnea. Exact numbers can vary slightly by insurer.
How long does a semaglutide prior authorization take to process?
Commercial plans typically take 3 to 14 days. Medicaid processing ranges from 7 to 21 days depending on the state. Urgent requests may be reviewed faster when health risks justify expedited handling.
Can I appeal a semaglutide prior authorization denial?
Yes, appeals are possible and often successful when additional documentation is submitted. Your doctor can provide a letter of medical necessity, updated labs, or comorbidity proof to strengthen the case.
What documentation is most important for semaglutide PA approval?
Key items include current BMI calculation, comorbidity records with labs or notes, proof of 3–6 months of failed lifestyle changes, and a physician letter explaining medical need and risks of not treating.
What happens if prior authorization is denied for Wegovy?
You can appeal with more evidence, pay out of pocket through manufacturer self-pay programs ($349–$499 monthly), or switch to compounded semaglutide ($199–$399 monthly) from licensed providers. Discuss alternatives with your doctor.
Dr. Usman is a medical content reviewer with 12+ years of experience in healthcare research and patient education. He specializes in evidence-based health information, medications, and chronic health topics. His work is based on trusted medical sources and current clinical guidelines to ensure accuracy, transparency, and reliability. Content reviewed by Dr. Usman is for educational purposes and does not replace professional medical advice.